Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss th...

Full description

Bibliographic Details
Main Authors: Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Denise M. Scholtens, Rohan Savoor, Bin Zhang, Jennifer D. Wu, Craig Horbinski, Rimas V. Lukas, David C. Binder, Derek A. Wainwright
Format: Article
Language:English
Published: Taylor & Francis Group 2019-03-01
Series:OncoImmunology
Subjects:
ido
immunotherapy
immunosuppression
brain tumor
glioblastoma
treg
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1548242

Internet

http://dx.doi.org/10.1080/2162402X.2018.1548242

Similar Items